Genelux Corp. (GNLX)
2.24
+0.24
(+12.00%)
USD |
NASDAQ |
Nov 18, 16:00
2.24
0.00 (0.00%)
After-Hours: 19:29
Genelux Shareholders Equity (Quarterly) : 9.178M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 9.178M |
| June 30, 2026 | 16.11M |
| March 31, 2026 | 22.92M |
| December 31, 2025 | 11.54M |
| September 30, 2025 | 18.59M |
| June 30, 2025 | 23.90M |
| March 31, 2025 | 29.85M |
| December 31, 2024 | 26.27M |
| September 30, 2024 | 33.09M |
| June 30, 2024 | 37.67M |
| March 31, 2024 | 15.08M |
| December 31, 2023 | 19.47M |
| Date | Value |
|---|---|
| September 30, 2023 | 24.03M |
| June 30, 2023 | 22.26M |
| March 31, 2023 | 2.691M |
| December 31, 2022 | -35.78M |
| September 30, 2022 | -32.33M |
| June 30, 2022 | -39.06M |
| March 31, 2022 | -36.54M |
| December 31, 2021 | -33.11M |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | -25.24M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.387B |
| Alnylam Pharmaceuticals, Inc. | 3.604B |
| Anika Therapeutics, Inc. | 137.58M |
| Savara, Inc. | 107.85M |
| Arrowhead Pharmaceuticals, Inc. | 50.31M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 20.61M |
| Total Liabilities (Quarterly) | 11.43M |
| Debt to Equity Ratio | 0.2554 |
| Current Ratio | 1.162 |
| Net Debt Paydown Yield | -0.11% |